Table 3: Combination therapy approaches in the treatment of EBV malignancies.

Lytic replication inducerDrugTarget cellsIn vivoReference

DNA methylase transferase inhibitors
5-AzacytidineGCV and 5-bromodeoxyuridineEBV+ and EBV- BL cellsNoneMoore et al. [75]

HDAC inhibitors
Arg-ButyrateGCVLCL from lung transplant recipientSingle human patientMentzer et al. [70]
Arg-ButyrateGCV10 human patientsMentzer et al. [76]
Arg-ButyrateGCV15 human patientsPerrine et al. [74]
Valproic Acid*Cisplatin, 5-FU, Gemcitabine, DoxorubicinLCL, gastric carcinoma-EBV, NPCSCID miceFeng et al. [77]
Na-ButyrateGCVP3HR1NoneGhosh et al. [78]

Radiation
γ-Radiation + Na-butyrateGCV & AZTLCL and BL cell linesSCID miceWestphal et al. [71]
γ-RadiationAZT+GCVLCL-4A1ANude ratsRoychowdhury et al. [79]

B-cell receptor blockade
Rituximab+DexamethasoneGCVAKATANude miceDaibata et al. [80]

Proteasome inhibitor
Bortezomib131I-FIAUBL cell lineSCID xenograftFu et al. [81]

Other
Cis-platinum, 5-fluorouracil, TaxolGCVGastric carcinoma, NPCNude miceFeng et al. [82]
Gemcitabine and DoxorubicinGCVLCL, and BL cell linesSCID miceFeng et al. [83]